Table 2 Open in new tab Risk of...

	Patients with outcome
All-cause mortality	1499	2951	0.717 (0.673–0.763)
Medical utilization
Hospital inpatient services	3444	6642	0.692 (0.664–0.721)^b
Emergency department services (ER)	3742	6484	0.756 (0.726–0.788)^b
Critical care services (ICU)	1176	2569	0.619 (0.578–0.664)
Mechanical ventilation	504	1236	0.537 (0.484–0.596)^b
	Mean ± SD	Mean ± SD	t-test (P value)
LDL-cholesterol	88.81 ± 51.58	88.19 ± 37.67	1.593 (P = 0.111)

Patients with outcome

Outcomes

PCSK9i users (n = 42 285)

Statin users (n = 42 285)

Adjusted hazard ratio (95% CI)^a

All-cause mortality

1499

2951

0.717 (0.673–0.763)

Medical utilization

Hospital inpatient services

3444

6642

0.692 (0.664–0.721)^b

Emergency department services (ER)

3742

6484

0.756 (0.726–0.788)^b

Critical care services (ICU)

1176

2569

0.619 (0.578–0.664)

Mechanical ventilation

504

1236

0.537 (0.484–0.596)^b

Mean ± SD

t-test (P value)

LDL-cholesterol

88.81 ± 51.58

88.19 ± 37.67

1.593 (P = 0.111)

	Patients with outcome
All-cause mortality	1499	2951	0.717 (0.673–0.763)
Medical utilization
Hospital inpatient services	3444	6642	0.692 (0.664–0.721)^b
Emergency department services (ER)	3742	6484	0.756 (0.726–0.788)^b
Critical care services (ICU)	1176	2569	0.619 (0.578–0.664)
Mechanical ventilation	504	1236	0.537 (0.484–0.596)^b
	Mean ± SD	Mean ± SD	t-test (P value)
LDL-cholesterol	88.81 ± 51.58	88.19 ± 37.67	1.593 (P = 0.111)

Table 2

Open in new tab

Risk of all-cause mortality and medical utilization (from 30 days post-index date to 5 years)

	Patients with outcome
Outcomes	PCSK9i users (n = 42 285)	Statin users (n = 42 285)	Adjusted hazard ratio (95% CI)^a
All-cause mortality	1499	2951	0.717 (0.673–0.763)
Medical utilization
Hospital inpatient services	3444	6642	0.692 (0.664–0.721)^b
Emergency department services (ER)	3742	6484	0.756 (0.726–0.788)^b
Critical care services (ICU)	1176	2569	0.619 (0.578–0.664)
Mechanical ventilation	504	1236	0.537 (0.484–0.596)^b
	Mean ± SD	Mean ± SD	t-test (P value)
LDL-cholesterol	88.81 ± 51.58	88.19 ± 37.67	1.593 (P = 0.111)

	Patients with outcome
Outcomes	PCSK9i users (n = 42 285)	Statin users (n = 42 285)	Adjusted hazard ratio (95% CI)^a
All-cause mortality	1499	2951	0.717 (0.673–0.763)
Medical utilization
Hospital inpatient services	3444	6642	0.692 (0.664–0.721)^b
Emergency department services (ER)	3742	6484	0.756 (0.726–0.788)^b
Critical care services (ICU)	1176	2569	0.619 (0.578–0.664)
Mechanical ventilation	504	1236	0.537 (0.484–0.596)^b
	Mean ± SD	Mean ± SD	t-test (P value)
LDL-cholesterol	88.81 ± 51.58	88.19 ± 37.67	1.593 (P = 0.111)

If the patient is less or equal to 10, results show the count as 10.

PCSK9i, proprotein convertase subtilisin/kexin type 9 inhibitors; CI, confidence interval; SD, standard deviation; LDL, low-density lipoprotein.

Propensity score matching was performed on age at index, male, race (White), social economic status (persons with potential health hazards related to socioeconomic and psychosocial circumstances), lifestyles (tobacco use, nicotine dependence, alcohol related disorders), medical utilization (office or other outpatient services, hospital inpatient, and observation care services), comorbidities (including hypertensive diseases, ischaemic heart diseases, cerebrovascular diseases, atherosclerosis, overweight and obesity, diabetes mellitus, vitamin D deficiency, chronic lower respiratory diseases, neoplasms, diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism, anxiety, dissociative, stress-related, somatoform and other non-psychotic mental disorders, chronic kidney disease (CKD), diseases of liver, sleep disorders), and laboratory results (LDL-C in serum or plasma).

Proportionality <0.001.

This Feature Is Available To Subscribers Only